Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, Jan. 11 '26)

Image
By G.M.

 


    BMJ

  1. FLINDERS M, Cairney P, Elliott IC
    Delivering change after the UK covid inquiry.
    BMJ. 2026;392:s18.
    PubMed        

  2. YAMEY G, Shaffer J
    Trump and RFK Jr are dismantling public health-aided and abetted by powerful doctors.
    BMJ. 2026;392:s19.
    PubMed        


    Clin Infect Dis

  3. RAO A, Johnson L, Bassit L, Sullivan J, et al
    Independent Testing to Accelerate the Development of Lateral Flow Assays for Influenza A, Influenza B and SARS-COV-2.
    Clin Infect Dis. 2026 Jan 9:ciaf660. doi: 10.1093.
    PubMed         Abstract available

  4. WANG XF, Calabrese C, Calabrese L
    Target Trial Emulation of Oral Antivirals for B-Cell-Depleted COVID-19 Patients-Reply to Chen et al.
    Clin Infect Dis. 2026 Jan 9:ciaf718. doi: 10.1093.
    PubMed        

  5. PURPURA L, Heisler T, Palmer S, Shah J, et al
    Overlapping Clinical Presentation of Long COVID and Postacute COVID-19 Vaccination Syndrome: Phenotypes, Severity, and Biomarkers.
    Clin Infect Dis. 2026 Jan 9:ciaf624. doi: 10.1093.
    PubMed         Abstract available


    Emerg Infect Dis

  6. WANG H, Embry T, Everhart K, Szekely M, et al
    Macrolide-Resistant Mycoplasma pneumoniae in Children, Ohio, USA.
    Emerg Infect Dis. 2025;31:2341-2343.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  7. WOODS A, Navarrete J, Li Q, Barbre K, et al
    SARS-CoV-2 infection rates among home dialysis patients and patients receiving hemodialysis at outpatient centers, January 2021-May 2023, United States.
    Infect Control Hosp Epidemiol. 2026 Jan 7:1-5. doi: 10.1017/ice.2025.10305.
    PubMed         Abstract available


    J Infect

  8. NESAMAR R, Crowther C, Chiveto DT, Pillay T, et al
    Humoral and cellular immunogenicity of COVID-19 vaccine boosters in participants with advanced HIV disease.
    J Infect. 2026 Jan 7:106676. doi: 10.1016/j.jinf.2026.106676.
    PubMed         Abstract available


    J Med Virol

  9. HUANG CY, Cheng CC, Chen SH, Cheng D, et al
    SARS-CoV-2 Spike Protein-Mediated Cardiac Dysfunction: Structural Abnormalities, Impaired Calcium Dynamics, and Gene Expression Changes in Human Stem Cell-Derived Cardiomyocytes.
    J Med Virol. 2026;98:e70789.
    PubMed         Abstract available


    J Virol

  10. ZHANG Z, Zeng Y, Lv Y, Li X, et al
    Salvianolic acid A exerts antiviral effects by targeting the S protein, a virulence factor of porcine epidemic diarrhea virus.
    J Virol. 2026 Jan 8:e0204325. doi: 10.1128/jvi.02043.
    PubMed         Abstract available

  11. MASTERS PS
    Coronavirus genome packaging and nucleocapsid assembly.
    J Virol. 2026 Jan 8:e0133025. doi: 10.1128/jvi.01330.
    PubMed         Abstract available

  12. HAZELL NC, Reyna RA, Adam A, Bonam SR, et al
    mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 in animal models.
    J Virol. 2026 Jan 7:e0189725. doi: 10.1128/jvi.01897.
    PubMed         Abstract available


    JAMA

  13. PRASAD V, Makary MA
    FDA Labeling Change for mRNA COVID-19 Vaccines-Reply.
    JAMA. 2026 Jan 7. doi: 10.1001/jama.2025.21754.
    PubMed        

  14. MEYEROWITZ EA
    FDA Labeling Change for mRNA COVID-19 Vaccines.
    JAMA. 2026 Jan 7. doi: 10.1001/jama.2025.21752.
    PubMed        


    Science

  15. KUPFERSCHMIDT K
    New conflicts erupt over key virus database.
    Science. 2026;391:116-117.
    PubMed         Abstract available

  16. CAVANAGH PE, Xue AG, Dai SA, Qiang A, et al
    Computational design of conformation-biasing mutations to alter protein functions.
    Science. 2026 Jan 8:eadv7953. doi: 10.1126/science.adv7953.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »